Helix BioPharma Strengthens Leadership Team with Strategic Appointments
TL;DR
Appointments of seasoned executives bring valuable experience and leadership to Helix BioPharma, enhancing competitive edge in oncology industry.
Veronika Kandziora and Jessica Kourniaktis join Helix BioPharma as COO and Director of Communications, respectively, to strengthen organizational structure and communication strategies.
Helix BioPharma's focus on developing novel therapies for hard-to-treat cancers aims to deliver better treatment options and improve patient outcomes, making the world a better place.
Ms. Kandziora's financial industry background and Ms. Kourniaktis' academic expertise bring diverse perspectives to Helix BioPharma, shaping a dynamic and innovative environment.
Found this article helpful?
Share it with your network and spread the knowledge!
Helix BioPharma, a clinical-stage oncology company, has appointed two key executives to accelerate its mission of developing treatments for hard-to-treat cancers. Veronika Kandziora joins as Chief Operating Officer, bringing over 20 years of leadership experience across biopharma, financial, and consulting sectors, while Dr. Jessica Kourniaktis assumes the role of Director of Communications.
Kandziora's appointment brings strategic continuity to the organization, leveraging her previous roles as Corporate Secretary and strategic consultant. With a background in finance and compliance, she aims to provide structural clarity and strategic alignment across the company. Her expertise spans international project management and regulatory environments, positioning her to strengthen Helix's operational foundation.
Dr. Kourniaktis enters her role with a unique background bridging academic research and communications strategy. Her experience in life sciences communications and leadership roles in biotechnology startups will be critical in articulating Helix's vision and engaging key stakeholders. As a former Teaching Fellow at the University of Oxford and a recipient of the Emerging Life Sciences CEO of the Year award, she brings a comprehensive perspective to the company's communication efforts.
CEO Thomas Mehrling emphasized the strategic importance of these appointments, noting that Kandziora and Kourniaktis will be instrumental in delivering on the company's vision of developing innovative cancer treatments. Their combined expertise in organizational leadership and strategic communications positions Helix to advance its pipeline of drug candidates targeting CEACAM6-expressing solid tumors.
The appointments come at a critical time for Helix, as the company continues to develop its lead candidate, Tumour Defence Breaker™ L-DOS47, an antibody-enzyme conjugate designed to neutralize the microenvironment of hard-to-treat solid tumors. These leadership changes signal the company's commitment to accelerating its research and communication strategies in the competitive oncology landscape.
Curated from NewMediaWire
